酒精摄入与癌症诊断患者的不良肿瘤学和治疗结果相关。作为一个关键的可改变行为因素，尤其是在治疗过程中，美国癌症幸存者的饮酒模式仍然未能得到充分研究。全面描述美国癌症幸存者的饮酒模式。本横断面研究使用了来自美国全美生物医学研究计划（All of Us Research Program）从2018年5月6日到2022年1月1日的数据，并在其中一个包含有电子健康记录（EHR）数据子集的1839名患者中进行了治疗。数据分析是从2022年10月1日到2023年1月31日进行的。现行饮酒和冒险饮酒行为的患病率，包括超过适量饮酒（每天饮用超过2杯），暴饮（一次饮用≥6杯）和有害饮酒（有关酒精使用障碍鉴定测试-饮用情况（AUDIT-C）得分≥3（女性）或≥4（男性））。 本研究包括15,199名成年人（基线时平均（SD）年龄为63.1（13.0）岁，其中9508名（62.6%）为女性）被诊断为患有癌症。总体而言，11,815名癌症幸存者（77.7%）是现行饮酒者。在现行饮酒者中，有1541人（13.0%）超过了适量饮酒，2812人（23.8%）报道了暴饮，4527人（38.3%）进行了有害饮酒。经过多元调整后，65岁以下的幸存者、男性或属于西班牙裔族裔、在18岁之前被诊断为癌症或有吸烟史的幸存者更有可能超过适量饮酒（<50岁：比值比[OR]，2.90 [95% CI，2.41-3.48]; 50-64岁：OR, 1.84[95% CI，1.58-2.15]; 男性：OR，2.38 [95% CI，2.09-2.72]; 西班牙裔族裔： OR，1.31 [95% CI，1.04-1.64]; 18岁之前被诊断：OR，1.52[95% CI，1.04-2.24]; 以前吸烟者：OR，2.46[95% CI，2.16-2.79]; 现在吸烟者：OR，4.14 [95% CI，3.40-5.04]）或暴饮（<50岁：OR，4.46[95% CI，3.85-5.15]; 50-64岁：OR，2.15[95% CI，1.90-2.43]; 男性：OR，2.10[95% CI，1.89-2.34]; 西班牙裔族裔： OR，1.31[95% CI，1.09-1.58]; 18岁之前被诊断：OR，1.71[95% CI，1.24-2.35]; 以前吸烟者：OR，1.69[95% CI，1.53-1.87]; 现在吸烟者：OR，2.27[95% CI，1.91-2.71]）。在电子健康记录中记录有接受治疗的1839名幸存者中，有1405人（76.4%）是现行饮酒者，其中170人（12.1%）超过了适量饮酒，329人（23.4%）报道了暴饮，540人（38.4%）从事了有害饮酒，“不同类型癌症治疗的患病率相似。 这项对美国多样化群体的横断面研究表明，酒精摄入和冒险饮酒行为在癌症幸存者中很常见，甚至在接受治疗的个体中也是如此。鉴于饮酒与不良治疗和肿瘤学结果的相关性，进一步研究和实施研究对于解决这一日益关注的癌症幸存者问题至关重要。

Alcohol consumption is associated with adverse oncologic and treatment outcomes among individuals with a diagnosis of cancer. As a key modifiable behavioral factor, alcohol consumption patterns among cancer survivors, especially during treatment, remain underexplored in the United States.To comprehensively characterize alcohol consumption patterns among US cancer survivors.This cross-sectional study used data from May 6, 2018, to January 1, 2022, from the National Institutes of Health All of Us Research Program, a diverse US cohort with electronic health record (EHR) linkage, and included 15 199 participants who reported a cancer diagnosis and 1839 patients among a subset with EHR data who underwent treatment within the past year of the baseline survey. Data analysis was performed from October 1, 2022, to January 31, 2023.Prevalence of current drinking and of risky drinking behaviors, including exceeding moderate drinking (>2 drinks on a typical drinking day), binge drinking (≥6 drinks on 1 occasion), and hazardous drinking (Alcohol Use Disorders Identification Test-Consumption [AUDIT-C] score ≥3 for women or ≥4 for men).This study included 15 199 adults (mean [SD] age at baseline, 63.1 [13.0] years; 9508 women [62.6%]) with a cancer diagnosis. Overall, 11 815 cancer survivors (77.7%) were current drinkers. Among current drinkers, 1541 (13.0%) exceeded moderate drinking, 2812 (23.8%) reported binge drinking, and 4527 (38.3%) engaged in hazardous drinking. After multivariable adjustment, survivors who were younger than 65 years, men, or of Hispanic ethnicity or who received a diagnosis before 18 years of age or ever smoked were more likely to exceed moderate drinking (aged <50 years: odds ratio [OR], 2.90 [95% CI, 2.41-3.48]; aged 50-64 years: OR, 1.84 [95% CI, 1.58-2.15]; men: OR, 2.38 [95% CI, 2.09-2.72]; Hispanic ethnicity: OR, 1.31 [95% CI, 1.04-1.64]; aged <18 years at diagnosis: OR, 1.52 [95% CI, 1.04-2.24]; former smokers: OR, 2.46 [95% CI, 2.16-2.79]; current smokers: OR, 4.14 [95% CI, 3.40-5.04]) or binge drink (aged <50 years: OR, 4.46 [95% CI, 3.85-5.15]; aged 50-64 years: OR, 2.15 [95% CI, 1.90-2.43]; men: OR, 2.10 [95% CI, 1.89-2.34]; Hispanic ethnicity: OR, 1.31 [95% CI, 1.09-1.58]; aged <18 years at diagnosis: OR, 1.71 [95% CI, 1.24-2.35]; former smokers: OR, 1.69 [95% CI, 1.53-1.87]; current smokers: OR, 2.27 [95% CI, 1.91-2.71]). Survivors with cancer diagnosed before 18 years of age or who ever smoked were more likely to be hazardous drinkers (aged <18 years at diagnosis: OR, 1.52 [95% CI, 1.11-2.08]; former smokers: OR, 1.83 [95% CI, 1.68-1.99]; current smokers: OR, 2.13 [95% CI, 1.79-2.53]). Of 1839 survivors receiving treatment as captured in the EHR, 1405 (76.4%) were current drinkers, and among these, 170 (12.1%) exceeded moderate drinking, 329 (23.4%) reported binge drinking, and 540 (38.4%) engaged in hazardous drinking, with similar prevalence across different types of cancer treatment.This cross-sectional study of a diverse US cohort suggests that alcohol consumption and risky drinking behaviors were common among cancer survivors, even among individuals receiving treatment. Given the adverse treatment and oncologic outcomes associated with alcohol consumption, additional research and implementation studies are critical in addressing this emerging concern among cancer survivors.